Physician profile
William Mckay
NPI 1265417331
$2,753.61
in general payments reported to CMS, 2019-2025
25 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $279 · 2021: $587 · 2022: $549 · 2023: $795 · 2024: $163 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $447.30 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $429.47 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $337.95 | 2019-2024 | Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $175.16 | 2019-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.41 | 2020-2023 | Xifaxan |
| Amgen INC. | $144.36 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $137.03 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $135.03 | 2019-2024 | Spravato |
| Merck Sharp & Dohme LLC | $112.20 | 2021-2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Novo Nordisk INC | $106.78 | 2019-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $105.01 | 2019-2023 | |
| Exact Sciences Corporation | $66.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $64.03 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $60.96 | 2019-2023 | Hetlioz, Fanapt |
| Abbott Laboratories | $46.75 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $33.07 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $32.88 | 2023 | Austedo Xr |
| Sun Pharmaceutical Industries INC. | $31.47 | 2021 | |
| Globus Medical, INC. | $28.39 | 2025 | Senza |
| Braeburn INC. | $21.11 | 2023 | Brixadi |
| Allergan, INC. | $16.92 | 2020 | |
| Dexcom, INC. | $16.20 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.16 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.21 | 2021 | |
| Collegium Pharmaceutical, INC. | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mckay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.